Compare iShares MSCI Taiwan ETF (EWT) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs GSK plc — how do they compare? iShares MSCI Taiwan ETF trades at $114.18 (market cap $12.74B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: GSK plc is far larger — about 7.2× iShares MSCI Taiwan ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and GSK plc for 93 Days on average.
| EWT | GSK | |
|---|---|---|
Market Cap | $12.74B | $91.88B |
Volume | 8,470,920 | 7,730,529 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $61.18 |
52-Week Low | $60.03 | $43.24 |
Typical Hold Time | 52 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $114.16, down 1.79% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights Taiwan's strategic position in AI supply chains with companies planning significant US investments.
The outlook remains positive given Taiwan's dominance in semiconductor manufacturing and AI growth potential, though geopolitical risks and concentration in technology stocks present notable challenges. Institutional interest continues with Bank of America increasing its stake, supporting the ETF's long-term growth narrative despite near-term volatility.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
